Phase 2 N=62 Effects of Tolcapone on Decision Making and Alcohol Intake in Alcohol Users
Alcohol Abuse · Impulsive Behavior
Primary: Number of Drinks Consumed in a Laboratory Bar Session — 2.69; 2.96; 2.73; 2.39 drinks
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=50 The ICON Study: Outcomes After FMT for Patients With IBD and CDI
Inflammatory Bowel Diseases · Clostridium Difficile Infection
Primary: Number of Participants With FMT Failure — 4 Participants
N/A N=17 Targeting Physical Health in Schizophrenia: Physical Activity Can Enhance Life
Schizophrenia · Schizoaffective Disorder · Brief Psychotic Disorder
Primary: Mean Difference in Participant's Total Distance During 6-Minute Walk From Baseline to Week 24 — 92.420 meters
Phase 3 N=32 Study to Learn More About the Potential of Antifungal Cream V61-044 Containing Trolamine to Cause Irritant Reaction of the Skin to Ultra Violet Light in Healthy Human Subjects
Dermatitis, Phototoxic
Primary: Phototoxic Reaction Evaluation Reported as Number of Test Site With Different Erythema Score — 77; 10; 85; 2 Test site
N/A N=5 Quantitative Characterization of Safe Irrigation for Ventricular Shunt Catheters
Hydrocephaly
Primary: To Demonstrate That the Flusher Can be Primed, Connected, and Activated in a Sterile Clinical Setting Per the Instructions for Use by the Treating Investigator . — 4; 4…
Phase 1 N=40 An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular Degeneration
Age-Related Macular Degeneration
Primary: Change From Baseline in Mean Standard Luminance Best-corrected Visual Acuity (BCVA) — 0.810; 0.526; 2.762; 1.833 letters
Phase 2 N=180 Bevacizumab, Temozolomide, and External Beam Radiation Therapy as First-Line Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Brain and Central Nervous System Tumors
Primary: Overall Survival — 19.6; 21.1 Months
Phase 2 N=40 A Trial of Placebo Versus Enzastaurin for Lung Cancer Prevention in Former Smokers
Lung Cancer
Primary: Change From Baseline in Percentage of Cells Staining Positive for Ki-67 in All Biopsy Specimens at Endpoint — 3.74; 6.15 percentage of cells with Ki-67 — p=0.556
Phase 2 N=35 A Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa
Hidradenitis Suppurativa
Primary: Number of Treatment-emergent Adverse Events (TEAEs) — 2; 6; 4; 1 Participants
Phase 2 N=36 Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM
Hematological Malignancies · Acute Lymphoblastic Leukemia (ALL) · Acute Myeloid Leukemia (AML)
Primary: Engraftment — 94 percentage of patients
N/A N=12 Exploratory Investigation of Data Obtained From a Sensor Connected to an Intermittent Catheter
Compliance, Patient
Primary: Number of Participants With Readability of Pressure Sensor Measurements — 11 Participants
N/A N=42 Repetitive Transcranial Magnetic Stimulation (rTMS) for Nicotine Addiction
Nicotine Dependence
Primary: Nicotine Consumption: Number of Cigarettes Per Day — 11.60; 13.73 the number of cigarette — p=0.05
Phase 4 N=35 Vaginal Estrogen for the Prevention of Recurrent Urinary Tract Infection in Postmenopausal Women
Recurrent Urinary Tract Infection
Primary: Occurrence of UTI During Randomization — 8; 10 Participants
Phase 3 N=501 Vitamin C, Thiamine, and Steroids in Sepsis
Sepsis
Primary: Vasopressor and Ventilator-free Days (VVFD) — 25; 26 days
Phase 2 N=35 Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab
Glioblastoma · Glioblastoma Multiforme · Gliosarcoma
Primary: Proportion of Patients That Have Progressive Survival (PFS) at Six Months From Patient Registration for Bevacizumab Naive Patients and PFS at 3 Months for Patients With…